for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Beigene Ltd

6160.HK

Latest Trade

80.70HKD

Change

1.90(+2.41%)

Volume

85,300

Today's Range

79.50

 - 

81.00

52 Week Range

61.05

 - 

105.30

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
78.80
Open
79.50
Volume
85,300
3M AVG Volume
1.46
Today's High
81.00
Today's Low
79.50
52 Week High
105.30
52 Week Low
61.05
Shares Out (MIL)
783.70
Market Cap (MIL)
61,755.89
Forward P/E
-11.61
Dividend (Yield %)
--

Next Event

Q3 2019 Beigene Ltd Earnings Release

Latest Developments

More

Beigene Posts HY Net Loss Attributable Of US$253.2 Million

Beigene Says FDA Accepted Co's New Drug Application For Zanubrutinib

BeiGene Announces U.S. FDA Acceptance And Grant Of Priority Review For Its New Drug Application Of Zanubrutinib

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Beigene Ltd

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and Pamiparib (BGB-290).

Industry

Biotechnology & Drugs

Contact Info

C/O Mourant Governance Services (Cayman)

94 Solaris Avenue, Camana Bay

+1.345.9494123

Executive Leadership

John Victor Oyler

Executive Chairman of the Board, Chief Executive Officer

Xiaobin Wu

General Manager, China and President

Howard Liang

Chief Financial Officer and Chief Strategy Officer

Eric E. Hedrick

Interim Chief Medical Officer, Immuno-Oncology

Jane Huang

Chief Medical Officer, Hematology

Key Stats

1.75 mean rating - 12 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.2K

2019(E)

0.4K
EPS (USD)

2018

-0.930

2019(E)

-0.866
Price To Earnings (TTM)
--
Price To Sales (TTM)
18.17
Price To Book (MRQ)
5.08
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
15.93
LT Debt To Equity (MRQ)
15.37
Return on Investment (TTM)
-40.04
Return on Equity (TTM)
-34.89

Latest News

UPDATE 2-Shanghai Junshi Biosciences soars on HK debut after $394 mln IPO

* Junshi Biosciences taking advantage of new listing rules in HK

UPDATE 1-China's Junshi Biosciences raises $394 mln after pricing IPO at bottom of range -sources

Chinese biotech startup Shanghai Junshi Biosciences Co Ltd has raised $394 million after pricing its Hong Kong initial public offering (IPO) at the bottom of a marketed range, two people familiar with the share sale said on Monday.

China's Junshi Biosciences raises $394 mln after pricing IPO at bottom of range -sources

Chinese biotech startup Shanghai Junshi Biosciences Co Ltd has raised $394 million after pricing its Hong Kong initial public offering (IPO) at the bottom of a marketed range, two people familiar with the share sale said on Monday.

China biotech Junshi Biosciences seeks up to $414 million in Hong Kong IPO

Chinese biotech company Shanghai Junshi Biosciences is seeking up to $414 million in a Hong Kong initial public offering (IPO), making it the latest company to take advantage of new listing rules to attract early-stage drug developers.

UPDATE 3-China's Innovent Biologics surges in Hong Kong debut

* Market volatility clouding prospects for other IPOs (Adds closing price, analyst comment)

UPDATE 2-China's Innovent prices HK IPO near top end, raises $421 mln -sources

* Company proceeded with IPO due to investor support -CFO (Adds context, company background)

China's Innovent Biologics looks to raise up to $422 mln in HK IPO - sources

Chinese biotech firm Innovent Biologics is looking to raise up to $422 million in its Hong Kong IPO, three sources said, in what could be the biggest biotech IPO in the financial hub this year.

U.S.-listed Chinese biotech Zai Lab plans Hong Kong float: sources

Zai Lab Ltd <ZLAB.O> is planning a Hong Kong float after its Nasdaq debut last year, in what would be the second U.S.-listed Chinese biotech firm to return to the city following an implementation of new listing rules, sources said.

Alibaba-backed online parenting firm Babytree eyeing up to $1 bln HK IPO -sources

* Babytree looking to raise $800 mln to $1 bln in HK IPO -sources

China Tower joins growing list of subdued Hong Kong IPO debuts

China Tower Corp Ltd's <0788.HK> shares closed flat on their debut in Hong Kong on Wednesday, with escalating Sino-U.S. trade tensions dragging on investor sentiment toward the world's biggest initial public offering (IPO) in two years.

Hong Kong's IPO market braces for China Tower debut after string of poor starts

* China Tower is world's biggest IPO in 2 years, raising $6.9 bln

Chinese biotech BeiGene raises $903 mln in HK's first secondary listing under new rules -sources

Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong - the first under new exchange rules - near the top of an indicative range, three people close to the deal said on Thursday.

HKEX chief welcomes secondary listings while China finalises CDRs

The chief executive of Hong Kong's stock exchange said overseas-listed Chinese firms were welcome to tap the territory's market for funds while waiting for mainland China to implement its own secondary listings plan.

BRIEF-Temasek Holdings (Private) Ltd Ups Share Stake In Mastercard, DowDuPont

* TEMASEK HOLDINGS (PRIVATE) LTD UPS SHARE STAKE IN MASTERCARD INC BY 35.7 PERCENT TO 1.25 MILLION CLASS A SHARES

UPDATE 1-Setback to Roche hopes for Tecentriq as fails key cancer trial

* Exelixis shares indicated 9.4 pct lower (Adds details about Exelixis, enrollment halt after patient deaths, Exelixis pre-market share price drop)

Setback to Roche hopes for Tecentriq as fails key cancer trial

Roche's hopes of its Tecentriq immunotherapy catching up rival medicines from Merck and Bristol-Myers Squibb were dealt a blow on Thursday after it failed a key combination trial.

BRIEF-Beigene Reports Q1 Net Loss per ADS $2.03

* REVENUES FOR THREE MONTHS ENDED MARCH 31, 2018 WERE $32.54 MILLION, COMPARED TO NIL IN SAME PERIOD IN 2017

BRIEF-BeiGene Says CEO John V. Oyler's 2017 Total Compensation Was $10.3 Million

* BEIGENE LTD SAYS CEO JOHN V. OYLER'S 2017 TOTAL COMPENSATION WAS $10.3 MILLION – SEC FILING Source : https://bit.ly/2r6wtIy Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Beigene Presents Clinical Data On Pamiparib In Chinese Patients With Ovarian Cancers At The American Association For Cancer Research Annual Meeting

* BEIGENE PRESENTS CLINICAL DATA ON PAMIPARIB IN CHINESE PATIENTS WITH OVARIAN CANCERS OR TRIPLE-NEGATIVE BREAST CANCER AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING

BRIEF-Beigene Initiates Global Phase 2 Trial Of Anti-PD-1 Antibody Tislelizumab

* BEIGENE INITIATES GLOBAL PHASE 2 TRIAL OF ANTI-PD-1 ANTIBODY TISLELIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MATURE T-AND NK-CELL LYMPHOMAS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up